Tandem Diabetes Care Issues Voluntary Pump Correction; Rosen Law Firm Probes Securities Claims
- • Tandem issued a voluntary device correction for select t:slim X2 pumps over a potential speaker fault causing insulin delivery interruptions. • The company is notifying customers and healthcare providers and guiding users on affected units and interim safety measures. • Tandem calls the action voluntary and precautionary, a targeted remediation to reduce therapy interruptions and mitigate patient safety risk.
Speaker Fault Prompts Device Correction at Tandem
Tandem Diabetes Care is issuing a voluntary medical device correction for select t:slim X2 insulin pumps after identifying a potential speaker‑related fault that can trigger an error and lead to discontinuation of insulin delivery. The company states in a press release dated Aug. 7, 2025 that the correction targets affected units to address the risk, and it is notifying customers and healthcare providers about the issue and the steps it is taking.
The company frames the action as a precautionary measure to restore normal device performance and reduce the likelihood of interruption to insulin therapy. Tandem does not describe a widespread hardware failure but flags the speaker component as a possible source of an error condition; affected pump users are being guided on whether their devices fall within the correction scope and on any interim safety measures. The notice emphasizes the voluntary nature of the correction and the company’s intent to mitigate patient safety risk through targeted remediation.
The development highlights product integrity and post‑market surveillance pressures for insulin‑pump manufacturers as devices become more complex and rely on multiple electronic subsystems. Insulin delivery interruptions can pose acute clinical risk for people with diabetes, prompting regulators and manufacturers to act quickly when device anomalies surface. Tandem’s announcement underscores ongoing industry challenges in balancing rapid innovation in automated insulin delivery with robust quality assurance and timely field corrections.
Law Firm Opens Investigations, Seeks Claimants
Rosen Law Firm, a global investor‑rights practice, is investigating potential securities claims on behalf of Tandem shareholders, alleging the company may have issued materially misleading business information related to the device correction. The firm is preparing a class action and invites purchasers of Tandem securities to submit claims, offering contingency‑fee representation and directing interested parties to online submission forms and contact lines.
The firm publicizes its securities litigation track record and urges investors to select qualified counsel, noting prior recoveries and rankings. Rosen provides direct contact information for its attorneys for those seeking to join the prospective class, while stressing that past results do not guarantee future outcomes.
